Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$21.39 - $49.64 $745,035 - $1.73 Million
34,831 New
34,831 $1.6 Million
Q1 2023

May 15, 2023

BUY
$16.88 - $34.24 $8.52 Million - $17.3 Million
504,608 Added 1192.98%
546,906 $9.76 Million
Q4 2022

Feb 14, 2023

BUY
$22.21 - $30.25 $939,438 - $1.28 Million
42,298 New
42,298 $1.23 Million
Q2 2022

Aug 15, 2022

BUY
$3.12 - $12.25 $401,010 - $1.57 Million
128,529 Added 35.64%
489,121 $2.03 Million
Q1 2022

May 16, 2022

BUY
$6.13 - $12.24 $287,423 - $573,909
46,888 Added 14.95%
360,592 $4.15 Million
Q4 2021

Feb 14, 2022

BUY
$8.62 - $13.9 $834,243 - $1.35 Million
96,780 Added 44.61%
313,704 $3.13 Million
Q3 2021

Nov 15, 2021

BUY
$11.68 - $20.72 $702,061 - $1.25 Million
60,108 Added 38.33%
216,924 $2.83 Million
Q2 2021

Aug 16, 2021

SELL
$18.52 - $22.55 $253,927 - $309,183
-13,711 Reduced 8.04%
156,816 $3.07 Million
Q1 2021

May 17, 2021

BUY
$20.25 - $39.49 $3.45 Million - $6.73 Million
170,527 New
170,527 $3.63 Million
Q1 2020

May 14, 2020

SELL
$13.16 - $22.9 $293,112 - $510,051
-22,273 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$19.53 - $25.5 $4.26 Million - $5.56 Million
-218,155 Reduced 90.74%
22,273 $511,000
Q3 2019

Nov 14, 2019

BUY
$18.62 - $24.51 $4.11 Million - $5.41 Million
220,573 Added 1110.92%
240,428 $5.19 Million
Q2 2019

Aug 14, 2019

BUY
$21.11 - $28.48 $246,522 - $332,589
11,678 Added 142.82%
19,855 $437,000
Q1 2019

May 14, 2019

BUY
$24.76 - $31.66 $202,462 - $258,883
8,177 New
8,177 $224,000
Q4 2018

Feb 14, 2019

SELL
$24.11 - $31.34 $462,767 - $601,539
-19,194 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$26.99 - $35.85 $251,222 - $333,691
-9,308 Reduced 32.66%
19,194 $560,000
Q2 2018

Aug 14, 2018

BUY
$17.02 - $35.2 $485,104 - $1 Million
28,502 New
28,502 $891,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $2.86B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.